TIRZEPATIDE

Course overview

TIRZEPATIDE IS A NOVEL MEDICATION THAT IS FDA APPROVED FOR THE TREATMENT OF TYPE 2 DIABETES MELLITUS. GIVEN ITS POTENT WEIGHT LOSS PROPERTIES, TIRZEPATIDE BE USED OFF-LABEL FOR OBESITY TREATMENT. IT WORKS AS A DUAL GLP-1 AGONIST AND GIP AGONIST TO MAXIMIZE SIMILAR BENEFITS THAT ARE SEEN WITH GLP-1 MEDICATIONS SUCH AS SEMAGLUTIDE. IT IS CURRENTLY IMPLEMENTED AS A SECOND-LINE DIABETES MEDICATION, SIMILAR TO GLP-1 MEDICATIONS, AND GIVEN AS A ONCE-A-WEEK SUBCUTANEOUS INJECTABLE. THE FDA APPROVED TIRZEPATIDE IN MAY 2022. THE MOST COMMONLY REPORTED ADVERSE EFFECTS ARE GASTROINTESTINAL, SUCH AS NAUSEA OR DIARRHEA. THIS ACTIVITY REVIEWS THE INDICATIONS, MECHANISM OF ACTION, ADVERSE EFFECTS AND CONTRAINDICATIONS, AND IMPORTANT PEARLS FOR THE USE OF TIRZEPATIDE. IN ADDITION, IT HIGHLIGHTS THE ADMINISTRATION, MONITORING, AND TOXICITY ASSOCIATED WITH TIRZEPATIDE FOR ALL CLINICIANS.